Previous 10 | Next 10 |
The following slide deck was published by TherapeuticsMD in conjunction with their 2018 Q4 earnings Read more ...
TherapeuticsMD (NYSEMKT: TXMD ): Q4 GAAP EPS of -$0.17 in-line. Revenue of $5.1M (+24.4% Y/Y) beats by $0.62M . Press Release More news on: TherapeuticsMD, Earnings news and commentary, Healthcare stocks news,
Successful Launch of IMVEXXY ® , Strong Positive Trends Continue for Prescriptions and Patient Refills BIJUVA™ Commercial Launch on Track for the Second Quarter of 2019 ANNOVERA™ Commercial Launch planned as Early as the Third Quarter of 2019 Conference Call Sched...
TherapeuticsMD (NYSEMKT: TXMD ) is scheduled to announce Q4 earnings results on Thursday, February 21st, after market close. More news on: TherapeuticsMD, Earnings news and commentary, , Healthcare stocks news, Read more ...
AAOI , ACIA , ADSW , AL , AMH , ANIK , APPN , ATUS , BEAT , BIDU , BJRI , BMRN , BOOM , BYD , CATM , CBPX , CENX , CHSP , COLD , CUBE , CWST , CZR , DBX , DXCM , EBS , ECOL , ED , ENV , EVRG , EXAS , FIX , FLR , FSLR , GMED , HALO , HCC , HPE , HTGC , ...
TherapeuticsMD's ( TXMD ) stock price has risen from a low of $3.51 in December '18 due to a combination of 1) market recovery and 2) great script count data. However, the stock price has once again remained under pressure with analysts citing: 1) lack of differentiation for Imvexxy and Bijuva...
-Executive Management to Host Conference Call on February 21, 2019 at 4:30 p.m. ET- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter and full year 2018 financial results on Thursday, February 21,...
Arlo Technologies (NYSE: ARLO ) -31% on Q4 earnings . More news on: Arlo Technologies, CCA Industries Inc, Catabasis Pharmaceuticals, Stocks on the move, Read more ...
TherapeuticsMD ( TXMD ) recently released an investor presentation with updated IMVEXXY launch metrics. The slide presentation contained vital information regarding the company's ongoing launch efforts. Not only was the data contained within the presentation encouraging, but the fact managemen...
Imvexxy 4 mcg dose now commercially available in the United States TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the commercial availability of Imvexxy™ (estradiol vaginal inserts) 4 mcg dose in the United States. ...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...